Advertisement
New Zealand markets closed
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NZD/USD

    0.5906
    +0.0000 (+0.01%)
     
  • NZD/EUR

    0.5526
    -0.0019 (-0.34%)
     
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • OIL

    83.08
    +0.35 (+0.42%)
     
  • GOLD

    2,405.70
    +7.70 (+0.32%)
     
  • NASDAQ

    17,234.71
    -159.61 (-0.92%)
     
  • FTSE

    7,870.18
    -6.87 (-0.09%)
     
  • Dow Jones

    37,955.53
    +180.15 (+0.48%)
     
  • DAX

    17,741.13
    -96.27 (-0.54%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • NZD/JPY

    91.2200
    -0.0340 (-0.04%)
     

Navigating Volatility: 3 Stocks Worthy of Consideration

Following a mixed session yesterday, investors remain focused on Jerome Powell’s testimony.

Needless to say, all are seeking clarification as we try to wade through a highly-unique economic backdrop and a year-long tightening campaign.

Powell believes returning to bigger rate hikes could be necessary if data suggests the U.S. economy is heating up again.

It’s worth noting that the Fed opted for a 25bps hike in its latest meeting, a step down from the prior 50bps hike in December and the 75bps hikes we saw in 2022.

And the market reacted to these comments accordingly, with stocks witnessing adverse price action in response.

ADVERTISEMENT

During times of heightened uncertainty, targeting low-beta stocks can provide a valuable shield to the broader market’s movements.

Three low-beta stocks – Fiserv FISV, Visa V, and Stryker SYK – could all be considerations for investors seeking heightened portfolio defense.

The chart below illustrates the performance of all three stocks year-to-date, with the S&P 500 blended in as a benchmark.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Let’s take a closer look at each one.

Fiserv

Fiserv is a global fintech and payments company with solutions for banking, global commerce, merchant acquiring, billing and payments, and point-of-sale. The stock presently carries a Zacks Rank #2 (Buy).

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Fiserv’s valuation multiples don’t appear stretched, with the current 16.1X forward earnings multiple sitting well beneath the 22.5X five-year median and the Zacks Business Services sector average.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In addition, it’s hard to ignore the company’s growth trajectory, with estimates suggesting 12.6% year-over-year earnings growth in its current fiscal year (FY23) and a further 14% in FY24.

The projected earnings growth comes on top of forecasted year-over-year revenue upticks of 6% in FY23 and 9% in FY24. Below is a chart illustrating the company’s revenue on an annual basis.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Visa

A multinational financial services company and a Zacks Rank #2 (Buy), Visa facilitates electronic funds transfers through Visa-branded debit, credit, and prepaid cards.

Visa posted a strong quarter in its latest release, exceeding the Zacks Consensus EPS Estimate by more than 8% and reporting revenue 3.4% above expectations.

The market was certainly pleased with the results, sending shares on an upward trajectory. This is illustrated by the green arrow in the chart below.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

In addition, Visa shares provide an income stream; V’s annual dividend currently yields 0.8%, a tick below the Zacks Business Services sector average.

Impressively, the company’s payout has grown by more than 15% over the last five years.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

And for the cherry on top, Visa is a cash-generating machine; V reported free cash flow of $3.9 billion in its latest release.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Stryker Corp.

Stryker is a medical device company operating in the global orthopedic market. Like the stocks above, SYK sports a Zacks Rank #2 (Buy).

Shares got a big boost following Stryker’s latest quarterly release. The company posted earnings of $3.00 per share, nearly 6% above expectations.

Quarterly revenue totaled $5.2 billion, 5% ahead of estimates and growing 10.7% year-over-year.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Similar to V, Stryker shares pay a dividend, currently yielding 1.1% annually. While the yield is below the Zacks Medical sector average, SYK’s 10% five-year annualized dividend growth rate picks up the slack.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Bottom Line

With an upcoming jobs report and investors digesting Powell’s testimony, it’s reasonable to expect a heightened level of volatility throughout the week.

In uncertain times, low-beta stocks, including Fiserv FISV, Visa V, and Stryker SYK, can help shield investors from spooky price swings.

In addition to being low-beta, all three sport a favorable Zacks Rank, indicating an optimistic near-term outlook.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Visa Inc. (V) : Free Stock Analysis Report

Stryker Corporation (SYK) : Free Stock Analysis Report

Fiserv, Inc. (FISV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research